|
|
Post by mytakeonit on Jan 7, 2019 13:57:31 GMT -5
IMO - 8 weeks out means that we will be MARCHing across the finish line. 8 more weeks and we will be running across that finish line.
But, that's mytakeonit
|
|
|
|
Post by mannmade on Jan 7, 2019 14:15:25 GMT -5
Imho 8 weeks out means “we’ll see...”. Am long term optimistic but honestly think short term is more of same. Bit of a grind for at least next six to nine months w slow but steady progress...
Am looking for approval of second Uthr molecule and another outside molecule possibly from RLS or maybe Novartis. Just speculation on my part. Until scripts get to a weekly net revenue point that shows a history of steady growth that is meaningful (whatever that means) which can be projected to future earnings WS will continue to ignore mnkd. Unless of course mnkd adds two or three molecule deals this year.
|
|
|
|
Post by sportsrancho on Jan 7, 2019 15:08:02 GMT -5
Six or nine months is not going to cut it, they need to get this moving now! Within the next three months. Or I suspect they have some decisions to make.
|
|
|
|
Post by mytakeonit on Jan 7, 2019 15:22:15 GMT -5
|
|
|
|
Post by mytakeonit on Jan 7, 2019 16:29:25 GMT -5
Just giving you my 2 cents worth ... YES !!! We got the first 2 cents today ... !!!
|
|
|
|
Post by nylefty on Jan 7, 2019 16:34:54 GMT -5
I have a good ad blocker and didn't see an ad. What did it say? |
|
|
|
Post by nylefty on Jan 7, 2019 16:40:48 GMT -5
In the conference call, Mike talked about the targeted Afrezza TV ad campaign starting on Jan 14, 2019. In the Q&A, he recants the story about Q4 2017 when Mannkind ran a TV pilot campaign. In the audio webcast at 15:45, Mike clearly states, "we learned that within 6 to 8 weeks we saw significant increase in new writers, new prescriptions, and then ultimately led to total prescriptions and total writers." ........... "Now we have the ability to sustain consumer advertising." 8 weeks from Jan 14 The commercial ran heavy in October and November up until December 2nd. 6-8 weeks from that time period is...... You guessed it, Right now. So no, there's no need to wait 8 weeks from Jan 14. But it ran in a relatively few markets, including some smaller ones like Las Vegas. Sounds like the new campaign will be much bigger. |
|
|
|
Post by mytakeonit on Jan 7, 2019 16:46:55 GMT -5
I have a good ad blocker and didn't see an ad. What did it say? It said remove your ad blocker !!! It was a Carlos Santana ad about  Carlos was playing and showing his fabulous guitar. Wow!!! |
|
|
|
Post by compound26 on Jan 7, 2019 17:01:37 GMT -5
Six or nine months is not going to cut it, they need to get this moving now! Within the next three months. Or I suspect they have some decisions to make. @sportsrancho Are you expecting hokey stick growth for Afrezza? I am with mannmade on this isue. At this point, I am do expect hokey stick growth for Afrezza at all. If it comes, it is a bonus for me. I do not count on it. As long as we can grow at current pace (2018's TRx over 2017 is about 159%; in other words, the growth rate is about 60% annualized), I think we will be fine. I recall reading that Dexcom CGM's annual sales grew at about 50% annually before it finally break even. |
|
|
|
Post by LongMNKD on Jan 7, 2019 17:24:07 GMT -5
In the conference call, Mike talked about the targeted Afrezza TV ad campaign starting on Jan 14, 2019. In the Q&A, he recants the story about Q4 2017 when Mannkind ran a TV pilot campaign. In the audio webcast at 15:45, Mike clearly states, "we learned that within 6 to 8 weeks we saw significant increase in new writers, new prescriptions, and then ultimately led to total prescriptions and total writers." ........... "Now we have the ability to sustain consumer advertising." 8 weeks from Jan 14 Mike also called the commercial "award winning". I'd like to see those awards, and find it very unlikely. The commercial didn't even show off afrezza's best feature, it's ease of use and design. I think they need a better commercial. |
|
|
|
Post by mytakeonit on Jan 7, 2019 17:25:49 GMT -5
Sorry people ... I tried playing that you tube video and found that the ad before it changes. Too bad ... so sad
|
|
|
|
Post by mango on Jan 7, 2019 17:32:23 GMT -5
I can't imagine how F*cked the future would be if Endos were the thought leaders of medical Cannabis.
|
|
|
|
Post by peppy on Jan 7, 2019 17:33:50 GMT -5
In the conference call, Mike talked about the targeted Afrezza TV ad campaign starting on Jan 14, 2019. In the Q&A, he recants the story about Q4 2017 when Mannkind ran a TV pilot campaign. In the audio webcast at 15:45, Mike clearly states, "we learned that within 6 to 8 weeks we saw significant increase in new writers, new prescriptions, and then ultimately led to total prescriptions and total writers." ........... "Now we have the ability to sustain consumer advertising." 8 weeks from Jan 14 Mike also called the commercial "award winning". I'd like to see those awards, and find it very unlikely. The commercial didn't even show off afrezza's best feature, it's ease of use and design. I think they need a better commercial. Afrezza® Inhaled Insulin Television Advertising Campaign Wins Gold Award for Creativity WESTLAKE VILLAGE, Calif., Oct. 15, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, was recently awarded top honors for its first Afrezza® TV commercial, “Unexpected Moments,” at the Medical Marketing & Media (MM&M) awards ceremony last week. The company worked with precisioneffect, a Boston-based healthcare advertising agency, to produce the advertisement. “Managing mealtime control is crucial in order to help individuals living with diabetes optimize their outcomes,” said Michael Castagna, CEO of MannKind Corporation. “Recent data published from the STAT study showed that Afrezza is associated with significant reductions in post-meal glucose excursions in patients with type 1 diabetes compared to an injected rapid-acting insulin. Our light-hearted ad, which showcases magical moments when food appears seemingly out of nowhere, drives home the message that it’s impossible to plan perfectly around meals. We are pleased that we are bringing awareness to this topic and can showcase Afrezza as an alternative to injected insulin at mealtimes.” Since its launch in July 2017, the television ad has contributed to increased interest in Afrezza, and a rise in sales and new prescriptions in the markets it has aired. “We are thrilled to have had the opportunity to partner with MannKind and help spread awareness about Afrezza through a campaign as unique as its product,” said Carolyn Morgan, President, precisioneffect. The Medical Marketing & Media annual awards program is the premier healthcare advertising awards show to recognize and champion both creativity and effectiveness in healthcare marketing and communications. The winning Afrezza TV advertisement can be seen here: www.youtube.com/watch?v=INHz5-I35DAglobenewswire.com/news-release/2018/10/15/1621242/0/en/Afrezza-Inhaled-Insulin-Television-Advertising-Campaign-Wins-Gold-Award-for-Creativity.html |
|
|
|
Post by mango on Jan 7, 2019 17:42:30 GMT -5
If the Cannabis community can achieve what we have against even greater odds and resistance, then we can without a doubt rise victorious with Afrezza.
It's time...
TO GO NUCLEAR
|
|
|
|
Post by Omega on Jan 7, 2019 18:02:12 GMT -5
Mike also called the commercial "award winning". I'd like to see those awards, and find it very unlikely. The commercial didn't even show off afrezza's best feature, it's ease of use and design. I think they need a better commercial. Afrezza® Inhaled Insulin Television Advertising Campaign Wins Gold Award for Creativity WESTLAKE VILLAGE, Calif., Oct. 15, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, was recently awarded top honors for its first Afrezza® TV commercial, “Unexpected Moments,” at the Medical Marketing & Media (MM&M) awards ceremony last week. The company worked with precisioneffect, a Boston-based healthcare advertising agency, to produce the advertisement. “Managing mealtime control is crucial in order to help individuals living with diabetes optimize their outcomes,” said Michael Castagna, CEO of MannKind Corporation. “Recent data published from the STAT study showed that Afrezza is associated with significant reductions in post-meal glucose excursions in patients with type 1 diabetes compared to an injected rapid-acting insulin. Our light-hearted ad, which showcases magical moments when food appears seemingly out of nowhere, drives home the message that it’s impossible to plan perfectly around meals. We are pleased that we are bringing awareness to this topic and can showcase Afrezza as an alternative to injected insulin at mealtimes.” Since its launch in July 2017, the television ad has contributed to increased interest in Afrezza, and a rise in sales and new prescriptions in the markets it has aired. “We are thrilled to have had the opportunity to partner with MannKind and help spread awareness about Afrezza through a campaign as unique as its product,” said Carolyn Morgan, President, precisioneffect. The Medical Marketing & Media annual awards program is the premier healthcare advertising awards show to recognize and champion both creativity and effectiveness in healthcare marketing and communications. The winning Afrezza TV advertisement can be seen here: www.youtube.com/watch?v=INHz5-I35DAglobenewswire.com/news-release/2018/10/15/1621242/0/en/Afrezza-Inhaled-Insulin-Television-Advertising-Campaign-Wins-Gold-Award-for-Creativity.html |
|
Carlos was playing and showing his fabulous guitar. Wow!!!
